Lower-dose decitabine improves clinical response compared with best supportive care in lower-risk MDS patients: a prospective, multicenter phase 2 study.
J Cancer
; 12(10): 2975-2981, 2021.
Article
in En
| MEDLINE
| ID: mdl-33854598
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Clinical_trials
/
Etiology_studies
/
Risk_factors_studies
Language:
En
Journal:
J Cancer
Year:
2021
Document type:
Article
Affiliation country:
China
Country of publication:
Australia